Details About Generic Salt ::  Aminoglu

Main Medicine Class::    

(ah-MEE-no-glue-TETH-ih-mide)

Cytadren

Tablets

250 mg

Class: Adrenal cortex suppressant

 Indications Suppression of adrenal function in patients with Cushing syndrome.

Suppression of adrenal function in advanced breast carcinoma or metastatic prostate carcinoma.

 Contraindications Standard considerations.

 Route/Dosage

Cushing Syndrome

ADULTS: PO 250 mg q 6 hr. Titrate to adrenal response in increments of 250 mg/day q 1 to 2 wk. Max daily dose is 2000 mg.

Dosage Adjusment

ADULTS: PO Dosage reduction may be required for a Ccr < 10 mL/min; specific guidelines are not established.

Discontinue therapy if patient develops severe rash or rash that lasts > 5 to 8 days. Therapy may be continued at a lower dose after resolution of mild to moderate skin rashes.

Interactions

CNS depressants

Concurrent use with CNS depressants (eg, narcotics, analgesics, alcohol, antiemetics, benzodiazepines, sedatives, tranquilizers) may potentiate CNS effects.

Dexamethasone, digitoxin, medroxyprogesterone, tamoxifen, theophylline, warfarin

Aminoglutethimide increases oxidative metabolism of these drugs. Higher doses of these agents may be required to achieve therapeutic response during concomitant therapy.

Lab Test Interferences None well documented.

 Adverse Reactions

CARDIOVASCULAR: Orthostatic or persistent hypotension; tachycardia. CNS: Headache; dizziness; drowsiness; lethargy. DERMATOLOGIC: Morbilliform rash; pruritus. ENDOCRINE: Adrenocortical insufficiency; hypothyroidism; masculinization and hirsutism in females. GI: Low potential for nausea and vomiting; elevated LFTs; cholestatic jaundice. GU: Aminoglutethimide crosses the placenta and has caused pseudohermaphroditism in female infants whose mothers took this agent and anticonvulsants during pregnancy. MUSCULOSKELETAL: Myalgia.

 Precautions

Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy not established. Cortical hypofunction: May cause adrenal cortical hypofunction, especially under conditions of stress. Hypotension: Aminoglutethimide may suppress aldosterone production by the adrenal cortex and may cause orthostatic or persistent hypotension. Monitor BP.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

• Adminster PO.
• Store at room temperature. Protect from light.

 Assessment/Interventions

• Adrenal function usually returns to normal within 36 to 72 hr of discontinuing aminoglutethimide, although recovery may be slower after prolonged therapy.
• Monitor plasma cortisol to assess response to therapy for suppression of adrenal function.
• Thyroid function may decrease during therapy. Monitor at baseline and throughout therapy. Some patients may require thyroid supplements.
• Monitor LFTs at baseline and throughout therapy.
• Monitor periodically for any electrolyte or hematologic changes.
• Patients may require replacement of mineralocorticoids with fludrocortisone. Patients may require replacement of glucocorticoids. Hydrocortisone 20 to 30 mg PO every morning replaces endogenous secretion. Discontinuation of aminoglutethimide and additional steroids may be required in situations that cause stress, such as shock, trauma, or infections.

OVERDOSAGE: SIGNS & SYMPTOMS   Ataxia, somnolence, lethargy, dizziness, fatigue, coma, hyperventilation, respiratory depression, nausea and vomiting, loss of sodium and water, hyponatremia, hypochloremia, hyperkalemia, hypoglycemia, hypovolemic shock caused by dehydration, hypotension

 Patient/Family Education

• May produce drowsiness or dizziness; use caution while driving or performing other tasks requiring alertness, coordination, or physical dexterity.
• May cause rash, fainting, weakness, or headache; notify health care provider if pronounced.
• Nausea and loss of appetite may occur during the first 2 wk of therapy; notify health care provider if these persist or become pronounced.

Medicscientist Drug Facts

Drugs Class ::

Indications for Drugs ::

 Indications Suppression of adrenal function in patients with Cushing syndrome.

Suppression of adrenal function in advanced breast carcinoma or metastatic prostate carcinoma.

Drug Dose ::

 Route/Dosage

Cushing Syndrome

ADULTS: PO 250 mg q 6 hr. Titrate to adrenal response in increments of 250 mg/day q 1 to 2 wk. Max daily dose is 2000 mg.

Dosage Adjusment

ADULTS: PO Dosage reduction may be required for a Ccr < 10 mL/min; specific guidelines are not established.

Discontinue therapy if patient develops severe rash or rash that lasts > 5 to 8 days. Therapy may be continued at a lower dose after resolution of mild to moderate skin rashes.

Contraindication ::

 Contraindications Standard considerations.

Drug Precautions ::

 Precautions

Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy not established. Cortical hypofunction: May cause adrenal cortical hypofunction, especially under conditions of stress. Hypotension: Aminoglutethimide may suppress aldosterone production by the adrenal cortex and may cause orthostatic or persistent hypotension. Monitor BP.

Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Orthostatic or persistent hypotension; tachycardia. CNS: Headache; dizziness; drowsiness; lethargy. DERMATOLOGIC: Morbilliform rash; pruritus. ENDOCRINE: Adrenocortical insufficiency; hypothyroidism; masculinization and hirsutism in females. GI: Low potential for nausea and vomiting; elevated LFTs; cholestatic jaundice. GU: Aminoglutethimide crosses the placenta and has caused pseudohermaphroditism in female infants whose mothers took this agent and anticonvulsants during pregnancy. MUSCULOSKELETAL: Myalgia.

Drug Mode of Action ::  

Drug Interactions ::

Interactions

CNS depressants

Concurrent use with CNS depressants (eg, narcotics, analgesics, alcohol, antiemetics, benzodiazepines, sedatives, tranquilizers) may potentiate CNS effects.

Dexamethasone, digitoxin, medroxyprogesterone, tamoxifen, theophylline, warfarin

Aminoglutethimide increases oxidative metabolism of these drugs. Higher doses of these agents may be required to achieve therapeutic response during concomitant therapy.

Drug Assesment ::

 Assessment/Interventions

• Adrenal function usually returns to normal within 36 to 72 hr of discontinuing aminoglutethimide, although recovery may be slower after prolonged therapy.
• Monitor plasma cortisol to assess response to therapy for suppression of adrenal function.
• Thyroid function may decrease during therapy. Monitor at baseline and throughout therapy. Some patients may require thyroid supplements.
• Monitor LFTs at baseline and throughout therapy.
• Monitor periodically for any electrolyte or hematologic changes.
• Patients may require replacement of mineralocorticoids with fludrocortisone. Patients may require replacement of glucocorticoids. Hydrocortisone 20 to 30 mg PO every morning replaces endogenous secretion. Discontinuation of aminoglutethimide and additional steroids may be required in situations that cause stress, such as shock, trauma, or infections.

Drug Storage/Management ::

 Administration/Storage

• Adminster PO.
• Store at room temperature. Protect from light.

Drug Notes ::

 Patient/Family Education

• May produce drowsiness or dizziness; use caution while driving or performing other tasks requiring alertness, coordination, or physical dexterity.
• May cause rash, fainting, weakness, or headache; notify health care provider if pronounced.
• Nausea and loss of appetite may occur during the first 2 wk of therapy; notify health care provider if these persist or become pronounced.

Medicscientist Drug Facts

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.